Phase I Dose Escalation Study of Telatinib, a Tyrosine Kinase Inhibitor of Vascular Endothelial Growth Factor Receptor 2 and 3, Platelet-Derived Growth Factor Receptor β, and c-Kit, in Patients With Advanced or Metastatic Solid Tumors

• Published in: Journal of clinical oncology Vol. 27; no. 25; pp. 4169 - 4176
• Main Authors: Eskens, Ferry A L M, Steeghs, Neeltje, Verweij, Jaap, Bloem, Johan L, Christensen, Olaf, van Doorn, Leni, Ouwerkerk, Jan, de Jonge, Maja J A, Nortier, Johan W R, Kraetzschmar, Joern, Rajagopalan, Prabhu, Gelderblom, Hans
• Format: Journal Article
• Language: English
• Published: United States American Society of Clinical Oncology 01-09-2009
• Subjects: Administration, Oral; Adolescent; Adult; Aged; Angiogenesis Inhibitors - administration & dosage; Angiogenesis Inhibitors - adverse effects; Angiogenesis Inhibitors - pharmacokinetics; Biomarkers, Tumor - blood; Contrast Media; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Magnetic Resonance Imaging; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasms - blood supply; Neoplasms - drug therapy; Neoplasms - enzymology; Neoplasms - pathology; Protein Kinase Inhibitors - administration & dosage; Protein Kinase Inhibitors - adverse effects; Protein Kinase Inhibitors - pharmacokinetics; Proto-Oncogene Proteins c-kit - drug effects; Pyridazines - administration & dosage; Pyridazines - adverse effects; Pyridazines - pharmacokinetics; Pyridines - administration & dosage; Pyridines - adverse effects; Pyridines - pharmacokinetics; Receptor, Platelet-Derived Growth Factor beta - antagonists & inhibitors; Time Factors; Treatment Outcome; Vascular Endothelial Growth Factor A - blood; Vascular Endothelial Growth Factor Receptor-2 - antagonists & inhibitors; Vascular Endothelial Growth Factor Receptor-2 - blood; Vascular Endothelial Growth Factor Receptor-3 - antagonists & inhibitors; Young Adult
• ISSN: 0732-183X; 1527-7755
• DOI: 10.1200/JCO.2008.18.8193

Telatinib (BAY 57-9352) is an orally available tyrosine kinase inhibitor of vascular endothelial growth factor receptor (VEGFR) -2, VEGFR-3, platelet-derived growth factor receptor-beta, and c-Kit. This phase I dose escalation study was conducted to evaluate the safety and tolerability of telatinib, with additional pharmacokinetic, pharmacodynamic, and efficacy assessments.
Patients with solid tumors refractory to standard therapies or with no standard therapy available were enrolled. Doses of continuously administered telatinib were escalated from 20 mg once daily to 1,500 mg twice daily.
Fifty-three patients were enrolled. Most frequently observed drug-related adverse events were nausea (26.4%; grade >or= 3, 0%) and hypertension (20.8%; grade 3, 11.3%; grade 4, 0%). Two dose-limiting toxicities were observed: one poorly controlled hypertension (600 mg twice daily), and one grade 2 weight loss, anorexia, and fatigue (1,500 mg twice daily). A formal maximum-tolerated dose was not reached. Telatinib was rapidly absorbed, with median time to peak concentration (t(max)) lower than 3 hours after dose. A nearly dose-proportional increase in exposure was observed with substantial variability. Telatinib half-life averaged 5.5 hours. Biomarker analyses showed dose-dependent increase in VEGF levels and decrease in plasma soluble VEGFR-2 levels, with a plateau at 900 mg twice daily. A decrease in tumor blood flow (K(trans) and IAUC(60)) was observed with dynamic contrast-enhanced magnetic resonance imaging. Best tumor response was stable disease, observed in 50.9% of patients.
Telatinib was safe and well tolerated up to 1,500 mg twice daily. Based on pharmacodynamic and pharmacokinetic end points, telatinib 900 mg twice daily is the recommended dose for subsequent phase II studies.